See more : Boku, Inc. (BOKU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Fennec Pharmaceuticals Inc. (FENC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fennec Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CS Communication & Systemes SA (SX.PA) Income Statement Analysis – Financial Results
- Reliance Power Limited (RPOWER.NS) Income Statement Analysis – Financial Results
- i3 Energy Plc (ITE.TO) Income Statement Analysis – Financial Results
- Macroblock, Inc. (3527.TWO) Income Statement Analysis – Financial Results
- Nichiban Co., Ltd. (4218.T) Income Statement Analysis – Financial Results
Fennec Pharmaceuticals Inc. (FENC)
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.25M | 1.54M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.68 |
| Cost of Revenue | 1.26M | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -55.23K | 0.00 |
| Gross Profit | 19.99M | 1.45M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.23K | 0.68 |
| Gross Profit Ratio | 94.08% | 94.40% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8,359,700.00% | 100.00% |
| Research & Development | 56.00K | 3.53M | 4.98M | 5.11M | 5.61M | 5.01M | 1.94M | 472.00K | 256.00K | 357.00K | 597.00K | 2.08M | 1.49M | 708.00K | 2.11M | 10.37M | 10.91M | 14.00M | 12.44M | 3.59M | 3.55M | 3.13M | 1.91M | 939.36K |
| General & Administrative | 20.59M | 17.72M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.12M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.71M | 20.51M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 1.94M | 3.90M | 1.21M | 3.52M | 3.28M | 2.88M | 3.18M | 3.49M | 1.78M | 907.40K | 738.72K | 614.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.00K | -17.00K | 6.00K | -8.00K | -14.00K | 0.00 | 0.00 | -3.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18M | 2.72M | 2.34M | 1.42M | 0.00 | 55.23K | 52.01K |
| Operating Expenses | 32.76M | 24.04M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.70M | 1.61M |
| Cost & Expenses | 34.06M | 24.12M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.65M | 1.61M |
| Interest Income | 441.00K | 195.00K | 54.00K | 87.00K | 322.32K | 0.00 | 0.00 | 0.00 | 3.00K | 2.00K | 2.00K | 25.00K | 43.00K | 32.00K | 47.00K | 286.00K | 833.00K | 0.00 | 361.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.39M | 978.00K | 126.00K | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00K | 11.00K | -444.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.00K | 149.00K | 17.22M | 402.00K | 13.01M | 10.41M | 6.95M | 2.87M | -1.23M | -699.00K | -1.00K | 20.00K | 43.00K | 3.25M | 615.00K | 164.00K | 192.00K | 2.43M | 3.06M | 2.52M | 1.61M | 123.76K | 55.23K | 52.01K |
| EBITDA | -12.36M | -22.59M | -123.00K | -17.89M | 234.00K | 521.00K | -95.00K | 82.00K | -1.89M | -2.88M | 1.79M | -5.18M | 4.55M | -4.60M | -2.60M | -13.89M | -14.19M | -17.91M | -19.27M | -12.56M | -5.22M | -4.24M | -2.79M | -2.59M |
| EBITDA Ratio | -58.18% | -1,468.60% | 0.00% | -10,579.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -421,928,118.14% | -231,162,432.56% |
| Operating Income | -12.77M | -22.59M | -17.22M | -17.89M | -13.01M | -10.41M | -6.95M | -2.87M | -1.89M | -2.88M | -1.93M | -3.62M | -3.44M | -4.60M | -3.22M | -13.89M | -14.19M | -19.06M | -18.35M | -9.42M | -6.74M | -4.04M | -2.65M | -1.61M |
| Operating Income Ratio | -60.09% | -1,471.60% | 0.00% | -10,520.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -400,900,112.25% | -237,629,943.17% |
| Total Other Income/Expenses | -3.27M | -1.13M | -123.00K | -224.00K | 234.00K | 521.00K | -95.00K | 82.00K | 1.28M | 701.00K | 3.78M | -1.54M | 8.12M | -3.51M | 204.00K | 0.00 | 905.96K | -1.54M | -3.99M | -227.00K | 79.44K | 321.36K | 194.17K | 8.31K |
| Income Before Tax | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -20.64M | -21.54M | -9.59M | -6.67M | -3.72M | -2.45M | -1.60M |
| Income Before Tax Ratio | -75.50% | -1,544.89% | 0.00% | -10,652.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| Income Tax Expense | 0.00 | 1.13M | 110.00K | -187.00K | -315.00K | -348.00K | -47.00K | -8.00K | -3.00K | -2.00K | -2.00K | -25.00K | -43.00K | 7.82M | 3.01M | 13.60M | 13.36M | -1.54M | -2.29M | -854.68K | -518.20K | 3.72M | 2.45M | 1.60M |
| Net Income | -16.05M | -24.84M | -17.46M | -17.92M | -12.46M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -19.10M | -19.25M | -8.74M | -6.15M | -3.72M | -2.45M | -1.60M |
| Net Income Ratio | -75.50% | -1,618.18% | 0.00% | -10,542.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| EPS | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.19 | -0.63 | 0.59 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -20.12 | -2.98 |
| EPS Diluted | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.17 | -0.62 | 0.58 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -4.04 | -2.98 |
| Weighted Avg Shares Out | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 18.94M | 14.99M | 12.68M | 10.83M | 9.87M | 9.72M | 8.20M | 7.99M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 122.02K | 536.64K |
| Weighted Avg Shares Out (Dil) | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 19.02M | 15.01M | 12.77M | 10.83M | 9.87M | 10.57M | 8.39M | 8.02M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 607.09K | 536.64K |
Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2023 financial results before the opening of...
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one...
Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Chase...
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update
~ Growing Physician Awareness and Usage of PEDMARK ® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30...
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2023 financial results before the opening of...
Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Raghuram...
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.14 per share a year ago.
Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of...
Fennec Pharmaceuticals Gains Momentum With Industry Endorsements
Fennec Pharmaceuticals received FDA approval for Pedmark, a drug addressing cisplatin-induced ototoxicity in pediatric patients. The National Comprehensive Cancer Network (NCCN) and the European Medicines Agency (EMA) have endorsed Pedmark, strengthening its market prospects.
Source: https://incomestatements.info
Category: Stock Reports